Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 6-month, double-blind, double-dummy, randomised, parallel group, multicenter, efficacy and safety study of Symbicort® pMDI 2x160/4.5μg and 2x80/4.5μg bid compared to Formoterol Turbuhaler, Budesonide pMDI (& the combination) and Placebo in chronic obstructive pulmonary disease patients (COPD)
To compare the efficacy (pre-post dose FEV1) of Symbicort® pMDI (pressurised Metered Dose inhaler) 2x 160/4.5μg/inhalation twice daily and of Symbicort® pMDI 2x 80/4.5μg/inhalation twice daily to its ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
Ensayo Clínico fase II aleatorizado, doble ciego, controlado con placebo, multicéntrico, para evaluar la eficacia y seguridad de ZACTIMA® en pacientes con Carcinoma papilar o folicular de Tiroides localmente avanzado o metastático que han fracasado al tratamiento con yodo radioactivo o que no son candidatos a recibirlo A Randomized, Double Blind, placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Zactima™ in Patients with advanced or metastatic papillary or follicular Thyroid Carcinoma failing or unsuitable for Radioiodine therapy
To demonstrate an improvement in progression free survival (PFS) with ZACTIMA™ (ZD6474) 300 mg as compared to Placebo in subjects with advanced or metastatic papillary or follicular Thyroid Carcinoma ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A double-blind, placebo controlled, randomised, parallel group, single centre, phase IIa study to investigate the efficacy, tolerability and safety of 8 doses of AZD8848 administered intranasally once weekly in mild to moderate allergic asthma patients challenged with an inhaled allergen
To evaluate the efficacy of AZD8848 on the Late Asthmatic Response (LAR) compared with placebo after 8 doses of once weekly intranasal administration in mild to moderate asthma patients challenged wit...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
SCORE An open, randomised, parallel, three treatment groups, multicentre, phase IV study - in real life - to compare the change in social outcome of quetiapine fumarate (Seroquel®) combined with Cognitive Remediation Therapy to conventional treatment in patients with schizophrenia
The primary objective of this study is to compare efficacy of quetiapine fumarate (hereafter called quetiapine) combined with Cognitive Remediation Therapy (CRT) to conventional treatment by evaluatin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
Safety and Efficacy of Two Doses of Anirfrolumab Compared to Placebo in Adult Subjects with Active Proliferative Lupus Nephritis
To evaluate the efficacy of anifrolumab plus standard of care (SOC) compared to placebo plus SOC in subjects with active proliferative lupus nephritis measured by the relative difference in change fro...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Phase III, Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety of Once Daily Esomeprazole for the Treatment of Clinically Diagnosed Gastroesophageal Reflux Disease (GERD) in Pediatric and Adolescent Patients 12 to 17 Years of Age, Inclusive
Primary: The primary objective of this study was to evaluate the safety and tolerability of once daily treatment with esomeprazole in pediatric and adolescent patients 12 to 17 years of age, inclusiv...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A single-centre, single-blind, randomised, placebo-controlled phase IIa study to investigate the effect of AZD1305 given as an iv infusion on left ventricular performance in patients with left ventricular dysfunction
To explore if AZD1305 compromises left ventricular function in patients with left ventricular dysfunction.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate chronic obstructive pulmonary disease (COPD)
To evaluate the efficacy of gefitinib tablets, 250 mg once daily (OD) on symptoms, mainly cough and sputum production, in patients with Chronic Obstructive Pulmonary Disease (COPD) compared to placebo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF)
The primary objective of this study is to demonstrate that AZD0837 is non-inferior to warfarin, aiming for an INR 2.0 to 3.0, target 2.5, in the prevention of the composite outcome variable of stroke ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) as Mono-Therapy in the Treatment of Elderly Patients with Major Depressive Disorder (SAPPHIRE STUDY)
The primary objective of this study is to evaluate the efficacy of quetiapine SR 50-300 mg/day versus placebo in elderly patients with MDD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
7
8
9
10
11
12
13
14
15
16
Suivant